Interpretation of the 2022 ICCE/AME Position Statement for Clinical Practice in Pituitary Prolactinoma: Update on Clinical Characteristics and Points of Diagnosis and Treatment of Pituitary Prolactinoma

doi:10.12114/j.issn.1007-9572.2023.0022

Abstract

Abstract:

Pituitary prolactinoma is a neuroendocrine disease caused by excessive pituitary prolactin-cell adenoma synthesis and prolactin secretion. The standardized diagnosis and treatment of pituitary prolactinoma in of great significance for recovering and maintaining pituitary function and improving life quality of the patients. In January 2022, the International Chapter of Clinical Endocrinology (ICCE) and the Italian Association of Clinical Endocrinologists (AME) published a position statement on pituitary prolactinoma in the European Journal of Endocrinology: 2022 ICCE/AME Position Statement for Clinical Practice in Pituitary Prolactinoma (abbreviated as 2022 ICCE/AME position statement) . Based on the latest medical evidence, 2022 ICCE/AME position statement conducts a systematic review, analysis and recommendations on the clinical diagnosis and treatment of pituitary prolactinoma. This article provides an update on the diagnosis and treatment of pituitary prolactinoma, special populations, dopamine agonist resistance, and invasive prolactinoma in the 2022 ICCE/AME position statement, which is hoped to be helpful to the awareness of pituitary prolactinoma among general practitioners and endocrinologists, and provide a reference for the clinical practice of standardized diagnosis and treatment.

Key words: Prolactinoma, Pituitary neoplasms, Hyperprolactinemia, Guideline, Prolactin, Dopamine agonists, Drug therapy

摘要：

垂体催乳素瘤是一种由垂体催乳素细胞瘤过量合成和分泌催乳素引起的神经内分泌疾病，垂体催乳素瘤的规范化诊疗对于恢复并维持患者的正常垂体功能并提高其生活质量具有重要意义。2022年1月，《欧洲内分泌杂志》发布了国际临床内分泌学分会（ICCE）与意大利临床内分泌学家协会（AME）关于垂体催乳素瘤的临床实践最新共识申明——《2022版ICCE/AME垂体催乳素瘤临床实践共识》（简称2022版ICCE/AME新共识）。2022版ICCE/AME新共识立足最新循证医学证据，对于垂体催乳素瘤的临床诊治问题进行系统性阐述、分析和建议。本文围绕2022版ICCE/AME新共识关于垂体催乳素瘤的诊断、治疗、特殊人群、多巴胺激动剂抵抗及侵袭性疾病等诊治要点更新进行解读，希望有助于全科医生及内分泌专科医生对于垂体催乳素瘤的认识，为其临床实践的规范化诊疗提供参考。

关键词: 催乳素瘤, 垂体肿瘤, 高催乳素血症, 指南, 催乳素, 多巴胺激动剂, 药物治疗

TAN Huiwen,LI Danting,YU Yerong. Interpretation of the 2022 ICCE/AME Position Statement for Clinical Practice in Pituitary Prolactinoma: Update on Clinical Characteristics and Points of Diagnosis and Treatment of Pituitary Prolactinoma[J]. Chinese General Practice, 2024, 27(06): 650-655. DOI: 10.12114/j.issn.1007-9572.2023.0022.
谭惠文,李丹婷,余叶蓉. 垂体催乳素瘤的临床特点及诊治要点更新——基于《2022版ICCE/AME垂体催乳素瘤临床实践共识》解读[J]. 中国全科医学, 2024, 27(06): 650-655. DOI: 10.12114/j.issn.1007-9572.2023.0022.

References 26

[1]	CHANSON P，MAITER D. The epidemiology，diagnosis and treatment of Prolactinomas：the old and the new[J]. Best Pract Res Clin Endocrinol Metab，2019，33（2）：101290. DOI：10.1016/j.beem.2019.101290.
[2]	VROONEN L，DALY A F，BECKERS A. Epidemiology and management challenges in prolactinomas[J]. Neuroendocrinology，2019，109（1）：20-27. DOI：10.1159/000497746.
[3]	MELMED S，CASANUEVA F F，HOFFMAN A R，et al. Diagnosis and treatment of hyperprolactinemia：an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab，2011，96（2）：273-288. DOI：10.1210/jc.2010-1692.
[4]	COZZI R，AMBROSIO M R，ATTANASIO R，et al. Italian Association of Clinical Endocrinologists（AME）and International Chapter of Clinical Endocrinology（ICCE）. Position statement for clinical practice：prolactin-secreting tumors[J]. Eur J Endocrinol，2022，186（3）：P1-33. DOI：10.1530/EJE-21-0977.
[5]	中国垂体腺瘤协作组. 中国垂体催乳素腺瘤诊治共识（2014版）[J]. 中华医学杂志，2014，94（31）：2406-2411. DOI：10.3760/cma.j.issn.0376-2491.2014.31.004.
[6]	BURTIS C A，ASHWOOD E R，BRUNS D E. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed[M]. Amsterdam：Elsevier，2018.
[7]	TSUR A，DREYFUSS E，NESS-ABRAMOF R，et al. Role of cannulated prolactin test in evaluation of hyperprolactinemia-a retrospective study[J]. Endocr Pract，2020，26（11）：1304-1311. DOI：10.4158/EP-2020-0260.
[8]	VILAR L，VILAR C F，LYRA R，et al. Pitfalls in the diagnostic evaluation of hyperprolactinemia[J]. Neuroendocrinology，2019，109（1）：7-19. DOI：10.1159/000499694.
[9]	PEUSKENS J，PANI L，DETRAUX J，et al. The effects of novel and newly approved antipsychotics on serum prolactin levels：a comprehensive review[J]. CNS Drugs，2014，28（5）：421-453. DOI：10.1007/s40263-014-0157-3.
[10]	BALAKRISHNAN C H，RAJEEV H. Correlation of serum prolactin level to child pugh scoring system in cirrhosis of liver[J]. J Clin Diagn Res，2017，11（7）：OC30-33. DOI：10.7860/JCDR/2017/24730.10273.
[11]	LO J C，BECK G J，KAYSEN G A，et al. Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis[J]. Hemodial Int，2017，21（2）：190-196. DOI：10.1111/hdi.12489.
[12]	KHAWAJA N M，TAHER B M，BARHAM M E，et al. Pituitary enlargement in patients with primary hypothyroidism[J]. Endocr Pract，2006，12（1）：29-34. DOI：10.4158/EP.12.1.29.
[13]	MCDONALD R J，LEVINE D，WEINREB J，et al. Gadolinium retention：a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates[J]. Radiology，2018，289（2）：517-534. DOI：10.1148/radiol.2018181151.
[14]	VERHELST J，ABS R，MAITER D，et al. Cabergoline in the treatment of hyperprolactinemia：a study in 455 patients[J]. J Clin Endocrinol Metab，1999，84（7）：2518-2522. DOI：10.1210/jcem.84.7.5810.
[15]	COLAO A，DI SARNO A，LANDI M L，et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists：a prospective study in 110 patients[J]. J Clin Endocrinol Metab，2000，85（6）：2247-2252. DOI：10.1210/jcem.85.6.6657.
[16]	ZAMANIPOOR NAJAFABADI A H，ZANDBERGEN I M，DE VRIES F，et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis[J]. J Clin Endocrinol Metab，2020，105（3）：e32-41. DOI：10.1210/clinem/dgz144.
[17]	HONEGGER J，NASI-KORDHISHTI I，ABOUTAHA N，et al. Surgery for prolactinomas：a better choice?[J]. Pituitary，2020，23（1）：45-51. DOI：10.1007/s11102-019-01016-z.
[18]	LAM G，MEHTA V，ZADA G. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas：review of the literature[J]. Neurosurg Focus，2012，32（6）：E2. DOI：10.3171/2012.4.FOCUS1268.
[19]	GILLAM M P，MOLITCH M E，LOMBARDI G，et al. Advances in the treatment of prolactinomas[J]. Endocr Rev，2006，27（5）：485-534. DOI：10.1210/er.2005-9998.
[20]	MOLITCH M E. Endocrinology in pregnancy：management of the pregnant patient with a prolactinoma[J]. Eur J Endocrinol，2015，172（5）：R205-213. DOI：10.1530/EJE-14-0848.
[21]	LUGER A，BROERSEN L H A，BIERMASZ N R，et al. ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy[J]. Eur J Endocrinol，2021，185（3）：G1-33. DOI：10.1530/EJE-21-0462.
[22]	BARRAUD S，GUÉDRA L，DELEMER B，et al. Evolution of macroprolactinomas during pregnancy：a cohort study of 85 pregnancies[J]. Clin Endocrinol（Oxf），2020，92（5）：421-427. DOI：10.1111/cen.14162.
[23]	COCKS ESCHLER D，JAVANMARD P，COX K，et al. Prolactinoma through the female life cycle[J].Endocrine，2018，59（1）：16-29. DOI：10.1007/s12020-017-1438-7.
[24]	GREENMAN Y. Prolactinomas and menopause：any changes in management?[J]. Pituitary，2020，23（1）：58-64. DOI：10.1007/s11102-019-00998-0.
[25]	GIUFFRIDA G，FERRAÙ F，LAUDICELLA R，et al. Peptide receptor radionuclide therapy for aggressive pituitary tumors：a monocentric experience[J]. Endocr Connect，2019，8（5）：528-535. DOI：10.1530/EC-19-0065.
[26]	CHILOIRO S，DE MARINIS L. From pituitary adenoma to pituitary neuroendocrine tumors：how molecular pathways may impact the therapeutic management?[J]. Endocr Metab Immune Disord Drug Targets，2021，21（10）：1744-1759. DOI：10.2174/1871530321666210226152901.